A phase II trial of nilotinib in the treatment of c-KIT mutated advanced acral and mucosal melanoma (NICAM).
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NICAM
- 10 Jun 2017 Biomarkers information updated
- 31 Aug 2014 Accrual to date is 912% according to United Kingdom Clinical Research Network record.
- 21 Aug 2014 Status changed from recruiting to completed according to United Kingdom Clinical Research Network record.